SCHEMBL6539629

SCHEMBL6539629

CCC(Oc1ccccc1[C]=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 11/20 0.40
SLC6A4 P31645 7/20 0.40
CYP1A2 P05177 4/20 0.40
CYP3A4 P08684 4/20 0.40
CYP2D6 P10635 4/20 0.40
TSHR P16473 3/20 0.40
SLC6A3 Q01959 3/20 0.40
KMT2A Q03164 2/20 0.40
CHRM1 P11229 2/20 0.40
ADRA2B P18089 2/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
HRH1 P35367 2/20 0.40
OPRM1 P35372 2/20 0.40
DRD3 P35462 2/20 0.40
OPRK1 P41145 2/20 0.40
HTR2B P41595 2/20 0.40
KCNH2 Q12809 2/20 0.40
KLF10 Q13118 2/20 0.40
HRH3 Q9Y5N1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6538638 0.88 SLC6A2 (0.44) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL17103224 0.78 MCHR1 (0.42) KMT2AMEN1LMNA
SCHEMBL6538619 0.76 SMN1; SMN2 (0.45) TSHRKMT2A
SCHEMBL1837438 0.75 TSHR (0.44) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL2763254 0.75 ALDH1A1 (0.48) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL14307918 0.73 ADRA2B (0.46) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
Methylamine SCHEMBL28551571 0.73 SLC6A2 (0.60) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
SCHEMBL1465246 0.73 IRAK4 (0.47) CYP1A2KMT2AADRA2BMEN1CYP2C19
SCHEMBL36373 0.72 LMNA (0.50) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6
Methylamine SCHEMBL28532168 0.72 SLC6A2 (0.61) SLC6A2SLC6A4CYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812235-B2 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-02 US disclosed
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ASTELLAS PHARMA INC. (JP) 2003-01-23 US disclosed
EP-1255748-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-13 EP disclosed
WO-2001060813-A1 BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018193-A1 Beta-alanine derivatives and their use as receptor anatgonists ARRB1, ADRB1, GLRB SLC6A2 125/4885SLC6A4 525/4885CYP1A2 600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.